EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy

Marine Geoffroy, Louna Pili, Valentina Buffa, Maëlle Caroff, Anne Bigot, Evelyne Gicquel, Grégory Rouby, Isabelle Richard iD, Romain Fragnoud

Cells · 2023

DOI: 10.3390/cells12202444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Marine Geoffroy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Généthon, 91000 Evry-Courcouronnes, France. Hauptthemen laut MEDLINE: Muscular Dystrophies, Limb-Girdle, Pentosyltransferases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Atamyo Therapeutics and Association Française contre les Myopathies (AFM-Téléthon).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Limb-Girdle Muscular Dystrophy R9 (LGMDR9) is a dystroglycanopathy caused by Fukutin-related protein (FKRP) defects leading to the deficiency of α-DG glycosylation, essential to membrane integrity. Recombinant adeno-associated viral vector (rAAV) gene therapy offers great therapeutic promise for such neuromuscular disorders. Pre-clinical studies have paved the way for a phase 1/2 clinical trial aiming to evaluate the safety and efficacy of FKRP gene therapy in LGMDR9 patients. To demonstrate product activity, quality, and consistency throughout product and clinical development, regulatory authorities request several quality controls, including a potency assay aiming to demonstrate and quantify the intended biological effect of the gene therapy product. In the present study, we generated FKRP knock-out (KO) cells fully depleted of α-DG glycosylation using CRISPR-Cas9 to assess the functional activity of a rAAV-FKRP gene therapy. We then developed a high-throughput On-Cell-Western methodology to evaluate the restoration of α-DG glycosylation in KO-FKRP cells and determine the biological activity of the FKRP transgene. The determination of the half maximal effective concentration (EC50) provides a method to compare the rAAV-FKRP batch using a reference standard. The generation of KO-FKRP muscle cells associated with the high-throughput On-Cell-Western technique may serve as a cell-based potency assay to assess rAAV-FKRP gene therapy products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophies, Limb-GirdlePentosyltransferasesHumansCell LineCRISPR-Cas SystemsDystroglycansGenetic TherapyMuscle, Skeletal

Stichwörter der Autor:innen

CRISPRFukutin-related protein (FKRP)Limb-Girdle Muscular Dystrophy Type 9gene therapyknock-outpotency assayrAAV

Substanzen

DystroglycansFKRP protein, humanPentosyltransferases

Autor:innen und Institutionen

  • Généthon, 91000 Evry-Courcouronnes, France.
  • Université Paris-Saclay/Université Evry, INSERM, Généthon, Integrare Research Unit, UMR_S951, 91000 Evry, France.
  • Institut de Myologie, Université Pierre et Marie Curie Paris 6, UM76 Univ. Paris 6/U974 UMR7215, CNRS Pitié-Salpétrière-INSERM, UMRS 974, 75000 Paris, France.
  • Atamyo Therapeutics, 91000 Evry, France.

ORCID-Profile: Isabelle Richard

Förderung

  • Atamyo Therapeutics and Association Française contre les Myopathies (AFM-Téléthon)

Zitieren

APA

Geoffroy, M., Pili, L., Buffa, V., Caroff, M., Bigot, A., Gicquel, E., Rouby, G., Richard, I., & Fragnoud, R. (2023). CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy. Cells. https://doi.org/10.3390/cells12202444

Vancouver

Geoffroy M, Pili L, Buffa V, Caroff M, Bigot A, Gicquel E, et al. CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy. Cells. 2023. doi:10.3390/cells12202444

BibTeX
@article{Geoffroy2023,
  author = {Geoffroy, Marine and Pili, Louna and Buffa, Valentina and Caroff, Maëlle and Bigot, Anne and Gicquel, Evelyne and Rouby, Grégory and Richard, Isabelle and Fragnoud, Romain},
  title = {CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12202444}
}
Kostenlos starten →